

## News Release

# Lonza to Showcase Its Latest Solutions for Enhanced QC Testing and Transfection at SLAS2018

**Walkersville, MD (USA) / Basel (CH), 7 December 2017**

– From 3-7 February 2018, Lonza will be exhibiting at SLAS2018, the annual show hosted by the Society for Laboratory Automation and Screening, in San Diego, CA (USA). At Booth 534 Lonza will showcase how its automated QC testing solutions and Nucleofector™ Devices can increase efficiency and throughput in the drug development process. In addition, Lonza is supporting a roundtable discussion on advanced *in vitro* cancer models for drug discovery and development.

### Automated Solutions for QC Testing

At SLAS2018 Lonza's QC testing experts will be on hand to demonstrate how the WinKQCL™ Endotoxin Detection and Analysis Software can interface with multiple robotic systems to provide a single database for data storage, management and reporting that complies with data-integrity regulations. At the Lonza booth, the team will also demonstrate how Lonza's MODA™ Solution can automate environmental monitoring, product testing and trending to help laboratories to move away from labor-intensive and error-prone paper reporting.

[www.lonza.com/WinKQCL](http://www.lonza.com/WinKQCL)  
[www.lonza.com/MODA](http://www.lonza.com/MODA)

### Scaling up Transfection for Drug Discovery

Lonza will showcase how its Nucleofector™ Technology enables efficient, sterile transfection of primary cells, stem cells and cell types that previously have been difficult to transfect. Also at Booth 534, Lonza's experts will demonstrate how the HT-Nucleofector™ Device can be combined with liquid-handling systems to automate transfection protocols, reducing the need for manual pipetting and helping to mitigate ergonomic stress. In addition, Lonza's innovative Nucleofector™ Devices allow transfection protocols to be scaled up without the need for reoptimization.

[www.lonza.com/ht-nucleofector](http://www.lonza.com/ht-nucleofector)  
[www.lonza.com/lv-unit](http://www.lonza.com/lv-unit)  
[www.lonza.com/transfection](http://www.lonza.com/transfection)

### Roundtable Discussion: Evaluation and Adoption of Advanced *in vitro* Cancer Models for Drug Discovery and Development

At SLAS2018 Lonza is supporting a roundtable discussion on *in vitro* cancer models for drug discovery and development. On Monday, 5 February, at from 12:30 pm to 2:30 pm in Room #3, top industry experts will deliver a series of presentations evaluating *in vitro* organ systems and advanced cancer models. Following the presentations a panel discussion will focus on the current trends and challenges with using the latest *in vitro* technologies for cancer research. More information about Lonza's roundtable discussion can be found at: <https://www.eventscribe.com/2018/SLAS2018/>

"We are looking forward to SLAS2018 – a highlight of the 2018 exhibition calendar," said Robert Porzio, Lonza's Product Manager for Endotoxin Detection. "Improving efficiency and throughput in the laboratory is important for advancing the drug development pipeline. At SLAS2018 we will demonstrate to scientists who visit the booth, how Lonza's latest products and software solutions can assist their research."

### About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings

and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at [www.lonza.com](http://www.lonza.com).

#### **Lonza Contact Information**

Lonza Cologne GmbH  
Manager Marketing Communications  
Petra Haberkamm  
Tel +49 221 991990  
[petra.haberkamm@lonza.com](mailto:petra.haberkamm@lonza.com)

Lonza Group Ltd  
Head External Communications  
Constance Ward  
Tel +41 61 316 8840  
[constance.ward@lonza.com](mailto:constance.ward@lonza.com)

#### **Additional Information and Disclaimer**

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited ("SGX-ST"). Lonza Group Ltd is not subject to the SGX-ST's continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.